# Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

> **NCT04913675** · PHASE3 · TERMINATED · sponsor: **Vir Biotechnology, Inc.** · enrollment: 1065 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** sotrovimab
- **BIOLOGICAL:** sotrovimab
- **BIOLOGICAL:** sotrovimab
- **BIOLOGICAL:** sotrovimab
- **BIOLOGICAL:** Sotrovimab
- **BIOLOGICAL:** Sotrovimab
- **BIOLOGICAL:** Sotrovimab

## Key facts

- **NCT ID:** NCT04913675
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-10
- **Primary completion:** 2022-07-19
- **Final completion:** 2023-03-24
- **Target enrollment:** 1065 (ACTUAL)
- **Why stopped:** The safety sub-study was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes
- **Last updated:** 2024-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04913675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04913675, "Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04913675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*